slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 82,351-82,380
Pages 3,950
Rows per page 30
Component
82,351-82,380 of 118,471
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
211
The slide uses a table to contrast the solubility of different diazoxide forms to undermine the company's rationale for their specific formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
216
Uses direct quotes from interviews to undermine the value proposition of the target company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
220
The slide uses a quote from a trial investigator to expose a potential safety oversight in study design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
222
Uses a combination of product imagery and user-generated content (Facebook post) to critique the competitor's dosing complexity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
224
The slide uses a Q&A transcript format to highlight negative sentiment from former employees.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
225
The slide uses direct quotes from an expert consultation to undermine the credibility of the drug's approval and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
226
The slide uses direct quotes from an ex-employee to build a case of corporate misconduct regarding clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
228
The slide uses a Q&A transcript format to highlight the alleged suppression of negative clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
233
The slide uses a Q&A transcript format to validate the activist's thesis regarding data manipulation and competitive threat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
235
The slide uses Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
236
The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
237
The slide uses a Q&A format to frame the contradiction between weight loss goals and diabetes risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
239
The slide uses a Q&A format to highlight specific concerns about data collection consistency and physiological noise (edema).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
240
The slide uses a Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
241
The slide uses a quote to establish credibility and validate the activist's research findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
242
The slide uses direct quotes from a Key Opinion Leader (KOL) to build a case against the drug's safety and market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
243
The slide uses a Q&A format to validate the primary claim made in the headline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
244
The slide uses direct quotes to build a case of corporate malfeasance regarding safety disclosures.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
245
The slide uses a 'quote-summary' structure to undermine the company's launch narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
248
The slide uses a Q&A transcript format to highlight potential safety concerns and lack of transparency regarding trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
251
The slide uses a Q&A format to highlight inconsistencies in clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
252
The slide uses direct quotes from a KOL to undermine the company's marketing narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
257
The slide uses a Q&A format to present expert testimony that undermines the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
259
The slide uses a 'Miller XR' moniker to highlight the perceived over-reliance on a single individual.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
260
The slide uses red boxes to highlight the name 'Jennifer Miller' across different study documents to emphasize her consistent involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit